Company news
Therapeuticsmd, Inc. (NASDAQ:TXMD) news
Therapeuticsmd, Inc. news releases on 6ix. Latest, Aug 11, 2026: TherapeuticsMD Announces Second Quarter 2026 Financial Results
Press releases & updates
TherapeuticsMD Announces Second Quarter 2026 Financial Results
August 11, 2026
TherapeuticsMD Announces First Quarter 2026 Financial Results
May 12, 2026
TherapeuticsMD : Amendment to Annual Report (Form 10-K/A)
April 1, 2026
TherapeuticsMD Announces Full Year 2025 Financial Results
March 30, 2026
TherapeuticsMD Announces Third Quarter 2025 Financial Results
November 12, 2025
TherapeuticsMD Announces Second Quarter 2025 Financial Results
August 12, 2025
TherapeuticsMD Announces First Quarter 2025 Financial Results
May 13, 2025
TherapeuticsMD Announces Full Year 2024 Financial Results
March 27, 2025
TherapeuticsMD Announces Third Quarter 2024 Financial Results
November 11, 2024
TherapeuticsMD Announces Second Quarter 2024 Financial Results
August 11, 2024
TherapeuticsMD Announces First Quarter 2024 Financial Results
May 9, 2024
TherapeuticsMD Announces Full Year 2023 Financial Results
March 28, 2024
TherapeuticsMD Announces Third Quarter 2023 Financial Results
November 13, 2023
TherapeuticsMD Announces Second Quarter 2023 Financial Results
August 13, 2023
TherapeuticsMD Announces First Quarter 2023 Financial Results
May 14, 2023
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
April 6, 2023
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
January 2, 2023
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
December 3, 2022
TherapeuticsMD Announces Third Quarter 2022 Financial Results
November 13, 2022
TherapeuticsMD Announces Additional $7 Million Private Placement
October 30, 2022
TherapeuticsMD Announces $7 Million Private Placement
October 2, 2022
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
September 11, 2022
TherapeuticsMD Announces Second Quarter 2022 Financial Results
August 14, 2022
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
August 7, 2022
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
July 31, 2022
TherapeuticsMD Announces Expiration of Tender Offer
July 12, 2022
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
May 30, 2022
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
May 19, 2022
TherapeuticsMD Announces First Quarter 2022 Financial Results
May 15, 2022
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
May 9, 2022
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
April 13, 2022
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
March 9, 2022
TherapeuticsMD Enters Into a Definitive Agreement to Divest vitaCare to GoodRx
March 6, 2022
TherapeuticsMD to Report Fourth Quarter 2021 Financial Results on March 10, 2022
February 28, 2022
U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®
December 9, 2021
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
December 7, 2021
TherapeuticsMD Announces Third Quarter 2021 Financial Results
November 10, 2021
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
November 10, 2021
TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021
October 26, 2021
TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer
October 14, 2021
Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month
September 1, 2021
TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector
August 22, 2021
TherapeuticsMD Announces Appointment of Hugh O’Dowd as President
August 8, 2021
TherapeuticsMD Announces Second Quarter 2021 Financial Results
August 3, 2021
TherapeuticsMD to Report Second Quarter 2021 Results on August 4, 2021
July 25, 2021
TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA
May 24, 2021
The Sun Sentinel Names TherapeuticsMD, Inc. a Winner of the South Florida Top Workplaces 2021 Award
May 23, 2021
TherapeuticsMD Announces First Quarter 2021 Financial Results
May 5, 2021
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetricians and Gynecologists 2021 Annual Meeting
May 2, 2021
TherapeuticsMD to Report First Quarter 2021 Results on May 6, 2021
April 28, 2021